The Latest

NOW AVAILABLE: For the International Biosimilars Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Benepali/Brenzys produced most of the promotional materials (46%) during this quarter. Overall, biosimilars highlighted comparability and safety when switching from biologics to biosimilars in Europe, while Canada promoted Brenzys as the first subcutaneous anti-TNF biosimilar approved in Canada that provides a low-cost therapy. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Ex-US-Q4-2016-Biosimilars

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Multiple Sclerosis Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q4 2016.

Overall, 122 new pieces were received for the Multiple Sclerosis market during Quarter 4, 2016. Out of the 14 brands observed, Biogen’s Tecfidera took the lead of promotional distribution and acquired 23% of the market’s overall volume. This increase was directly due to robust advertising of its new “Tecfidera Treatment” campaign. Also within Tecfidera’s analysis, patients were introduced to the new TecTrack mobile app, which provides patient assistance along the treatment journey. Education and support programs continued to be a cornerstone of promotional messaging across all brands, with emphasis on social media and public relation campaigns. These programs encouraged patients to join their online Facebook communities, attend live MS events, hear real patient stories on YouTube, and more. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Q4-MS

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online  database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com // Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European Psoriatic Arthritis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Humira produced the highest number of materials, capturing 26% of the promotional volume in the PsA market in Europe. Most brands focused on clinical studies to support efficacy and safety, while patient support and ease-of-use were important elements for therapy adherence such as Humira’s new 40 mg/0.4 mL presentation or Remicade’s Infusion Service. New indications for Humira and Cosentyx were promoted, and the introduction of new imagery was also present in biologics and biosimilars. Innovation and comparability were promotional highlights for biosimilars during this quarter. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Ex-US-Q4-2016-PsA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

During 2016, the Rheumatoid Arthritis market grew from a total of 13 competitive brands to 18 competitive brands, making this therapy area one of the most expansive markets from a promotional standpoint. This increase was due to the launch of three new biosimilar agents, Amjevita, Erelzi, and Inflectra, a new XR formulation for Xeljanz, and pipeline drug sarilumab. After completing a full year analysis, 410 new pieces were observed in circulation pertaining to the products available in the US for the treatment of RA. For the fourth year in a row, Pfizer’s Xeljanz franchise surpassed all other brands in the total volume of promotional materials that were distributed over the course of 2016. A noticeable marketing increase was seen for Medac’s Rasuvo as well as Janssen’s Remicade, who pushed back against its new adversary, Inflectra. Persistent marketing initiatives across the majority of brands included financial assistance offers, the promotion of long-standing clinical experience, and the introduction of new programs to help assist with patient adherence, such as Amgen’s STATWISE program and Pfizer’s Feedback Program.

2016-RA-Year-end

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com //  Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Biologics for RA Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q4 2016.

  • Overall, 106 new pieces were received for the Biologics for RA market during Quarter 4, 2016. Promotional volume attributed to Pfizer’s Xeljanz franchise was observed as the largest promotional distributor, capturing 22% of the market’s total volume.
  • Bristol-Myers Squibb launched a new DTC campaign for Orencia, which promoted RA symptom relief.
  • Janssen’s messaging pertaining to Remicade included references to “no interchangeable biosimilar” and also featured the launch of a new visual HCP campaign for Simponi Aria, which depicts a physician’s “Occupied Mind.”
  • AbbVie launched a new DTC campaign for Humira, which demonstrates how the product allows patients to “Go Further.”
  • Amgen introduced the term “Advancedmentality” to define its commitment to providing patient services.
  • Genentech/Biogen launched a new Rituxan campaign to encourage a different treatment approach sooner rather than later.
  • Medac’s Rasuvo materials featured a new marketing strategy promoting better disease control and GI tolerability compared to oral MTX.
  • Sanofi and Regeneron received a Complete Response Letter from the FDA regarding certain deficiencies that need to be resolved before the BLA for sarilumab can be approved.
  • Pfizer released the first branded materials announcing Inflectra’s approval and availability in the U.S.

Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

 

q4-ra

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:  US Markets: Christine Alongi at Alongi@dtwresearch.com //  Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European AS and axSpA Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Humira generated the highest number of materials, capturing 32% of the promotional volume in the AS and nr-axSpA markets in Europe. Most brands concentrated on clinical studies to support efficacy and safety, while patient support and ease-of-use were important elements for therapy adherence (e.g. Humira’s new 40 mg/0.4 mL presentation). Biosimilars emphasized innovation and comparability when switching from biologics to biosimilars. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Ex-US-Q4-2016-AS-axSpA

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Biologics for GI Indications Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Overall, the GI biologics market produced 40 pieces, making Humira the promotional leader with 45% of all pieces in Q4. Biologics focused on efficacy based on clinical studies, patient support with new services (e.g. “Infusion Service” for Remicade in Germany), and convenience promoted by enhanced products (e.g. 40 mg/0.4 mL presentation for Humira across Europe). Biosimilars mostly emphasized comparability and cost savings. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Ex-US-GI-Q4-2016

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the International RA Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Humira produced the highest number of materials, capturing 21% of the promotional volume. Most brands focused on clinical studies to support efficacy and safety, while patient support (eg. Remicade’s “Infusion Service” in Germany) and ease-of-use were important elements for therapy adherence. Biosimilars highlighted comparability when switching from biologics to biosimilars. Kevzara/Sarilumab is a new addition to the market with a pre-launch unbranded campaign in the UK. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

RA-ExUS-Q4-2016

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Psoriasis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Humira kept its status as promotions leader during Q4, producing 29% of the total promotional volume. Enbrel promoted its status as a biologic approved for PsO pediatric patients, while Humira featured its new enhanced presentation. The brands focused on patient convenience, new approvals, new clinical studies, and patient services, while biosimilars maintained comparability and cost-savings as main promotional messages. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

2016-Q4-Psoriasis

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Canadian and European MS Markets – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2016.

Overall, 62 new pieces were distributed for the Canadian and European MS markets, a slight decrease from last quarter. Gilenya captured the highest volume with 24% of promotional materials in Q3, replacing Tysabri as the promotions leader. The main topics were new patient support programs (e.g. CoPACT), efficacy based on real-life clinical studies (e.g. ATTAIN), and the introduction of a new therapy, Zinbryta. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-Q3-2016-MS

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with: